![]() “We have a product candidate designed to continuously deliver axitinib, a TKI with the highest binding affinity for the VEGF receptor currently in clinical development for the treatment of wet AMD and other VEGF-mediated retinal diseases. “We are very pleased to see this latest 10-month data that support OTX-TKI's potential to set a new standard for durability in the treatment of wet AMD,” said Antony Mattessich, President and Chief Executive Officer. The presentation can be accessed by visiting the scientific and medical presentations tab of the investor section of the Company’s website at. The data is being presented this morning at 8:00 am ET at the Angiogenesis, Exudation, and Degeneration 2023 Virtual Meeting by Andrew A. Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy and other retinal diseases. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced interim 10-month data from its U.S. 11, 2023 (GLOBE NEWSWIRE) - Ocular Therapeutix, Inc. OTX-TKI continued to be generally well tolerated with no drug-related serious adverse events through Month 10Ĭonference call to discuss results to be held on Monday, February 13 at 8:30 a.m. All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10ĬSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subjects and aflibercept treated subjects
0 Comments
Leave a Reply. |